N-[2-(二乙氨基)乙基]丙酰胺 | 63224-20-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-[2-(二乙氨基)乙基]丙酰胺
• 英文名称: N-(2-(Diethylamino)ethyl)propionamide
• 英文别名: Propanamide, N-(2-(diethylamino)ethyl)-；N-[2-(diethylamino)ethyl]propanamide
• CAS: 63224-20-4
• 化学式: C₉H₂₀N₂O
• mdl: MFCD01698660
• 分子量: 172.271
• InChiKey: ZJJAQVISALRGCN-UHFFFAOYSA-N

物化性质

• 沸点：
  77-78 °C(Press: 0.2 Torr)
• 密度：
  0.905±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-[2-(二乙氨基)乙基]丙酰胺 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 40.0h， 以76%的产率得到N,N-二乙基乙二胺
  参考文献：
  名称：

  Nucleophilic ring opening of 2-oxazolines with amines: a convenient synthesis for unsymmetrically substituted ethylenediamines

  摘要：

  DOI：

  10.1021/jo00199a029
• 作为产物：
  描述：

  2-乙基-2-唑啉 在 盐酸 作用下， 以 乙醚 、 乙腈 为溶剂， 生成 N-[2-(二乙氨基)乙基]丙酰胺
  参考文献：
  名称：

  2-Ethyl-4,5-dihydro-1,3-oxazole: A Useful Aziridine Equivalent for the Preparation of Substituted 1,2-Ethanediamines

  摘要：

  DOI：

  10.1055/s-1981-29518

文献信息

• Nicotinamide Derivatives
  申请人：Katsifis Andrew

  公开号：US20110178396A1

  公开（公告）日：2011-07-21

  A compound comprising a pyridine carboxamide structure, for use in imaging or treating melanoma, is described. An aromatic ring in the structure is substituted with a radiohalogen atom and the substitution on the amide nitrogen atom is such that the compound binds to melanin.

  描述了一种含有吡啶羧酰胺结构的化合物，用于成像或治疗黑色素瘤。结构中的芳香环被取代为一个放射性卤原子，酰胺氮原子上的取代使得该化合物与黑色素结合。
• Polyamine-substituted ligands for use as contrast agents
  申请人：Wolf Markus

  公开号：US20070202047A1

  公开（公告）日：2007-08-30

  The present invention relates to a polyamine-substituted ligand for the preparation of a contrast agent derived from a chelating molecule selected from the group consisting of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and diethylentriamine-pentaacetic acid (DTPA), wherein at least one of the carboxylic groups of the chelating molecule is reacted with an amine of formula HNR 1 R 2 to form an amide bond, wherein R 1 , R 2 are independently selected from the group consisting of H; (CH 2 ) n —NR 3 R 4 ; and R 5 ; R 3 , R 4 are independently selected from the group consisting of H; (CH 2 ) m —NR 6 R 7 ; and (CH 2 ) m-1 —CH 3 ; R 6 , R 7 are independently selected from the group consisting of H; and (CH 2 ) o-1 —CH 3 ; n, m, o are independently 2, 3, or 4; R 5 is of formula and optionally at least one of the carboxylic groups of the chelating molecule is further reacted with a monoalkylamine having 1 to 18 carbon atoms to form an amide bond; provided that at least one of R 1 , R 2 is other than H. Furthermore, the invention relates to contrast agents for magnetic resonance imaging (MRI) comprising said ligands and in-vivo diagnostic methods based on MRI using said contrast agents.

  本发明涉及一种用于制备对比剂的聚胺取代配体，所述对比剂源自从1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸（DOTA）和二乙烯三胺五乙酸（DTPA）组成的羧基配体中选择的螯合分子，其中所述螯合分子的羧基之一与公式HNR1R2的胺反应形成酰胺键，其中R1、R2独立地选择自H；（CH2）n—NR3R4；和R5；R3、R4独立地选择自H；（CH2）m—NR6R7；和（CH2）m-1—CH3；R6、R7独立地选择自H；和（CH2）o-1—CH3；n、m、o独立地为2、3或4；R5为公式，并且可选地，所述螯合分子的羧基之一进一步与具有1至18个碳原子的单烷基胺反应形成酰胺键；前提是R1、R2中至少一个不是H。此外，本发明涉及包括所述配体的磁共振成像（MRI）对比剂以及基于MRI使用所述对比剂的体内诊断方法。
• Polarity-Tuning Derivatization-LC-MS Approach for Probing Global Carboxyl-Containing Metabolites in Colorectal Cancer
  作者：Xiqing Bian、Na Li、Binbin Tan、Baoqing Sun、Ming-Quan Guo、Guoxin Huang、Li Fu、W. L. Wendy Hsiao、Liang Liu、Jian-Lin Wu

  DOI：10.1021/acs.analchem.8b01873

  日期：2018.10.2

  Carboxyl-containing metabolites (CCMs) widely exist in living systems and are the essential components for life. Global characteristics of CCMs in biological samples are critical for the understanding of physiological processes and the discovery for the onset of relevant diseases. However, their determination represents a challenge due to enormous polarity differences, structural diversity, high structural similarity, and poor ionization efficiency in mass spectrometry. Herein, 5-(diisopropylamino)amylamine (DIAAA) derivatization coupled with liquid chromatography–mass spectrometry (LC-MS) was developed for mapping the CCMs. With this methodology, the sensitivity was significantly enhanced. More importantly, the hydrophobicity of polar CCMs, amino acids, TCA cycle intermediates, and short-chain fatty acids and the hydrophilicity of low-polar CCMs, long-chain fatty acids, and bile acids were significantly increased, resulting in a remarkable separation efficiency for which 68 CCMs can be simultaneously determined. Furthermore, the polarity-tuning effect was confirmed to be induced by the different impacts of aliphatic chains and nitrogen atom in DIAAA, the latter existing as a cation in the acidic mobile phase, using different derivatization reagents. Finally, this derivatization method was utilized to hunt for the potential biomarkers in colorectal cancer (CRC) patients and 52 CCMs, related with several key metabolic pathways, including amino acids metabolism, TCA cycle, fatty acid metabolism, pyruvate metabolism, and gut flora metabolism were identified. This innovative polarity-tuning derivatization-LC-MS approach was proved to be a valuable tool for probing global metabolome with high separation efficiency and sensitivity in various biological samples.

  含羧基代谢物（CCMs）广泛存在于生物系统中，是生命的基本组成部分。CCMs在生物样本中的全球特征对于理解生理过程和发现相关疾病的发生具有重要意义。然而，由于极性差异巨大、结构多样性、高结构相似性和在质谱中的离子化效率较低，它们的测定面临挑战。在此，我们开发了5-(二异丙基氨基)戊胺（DIAAA）衍生化结合液相色谱-质谱（LC-MS）的方法以绘制CCMs的分布。通过这种方法，灵敏度显著提高。更重要的是，极性CCMs、氨基酸、TCA循环中间体和短链脂肪酸的疏水性显著增强，而低极性CCMs、长链脂肪酸和胆汁酸的亲水性也显著增加，从而实现了卓越的分离效率，使得68种CCMs可以同时测定。此外，极性调节效应被证实是由于DIAAA中脂肪链和氮原子的不同影响所引起的，后者在酸性流动相中以阳离子的形式存在，使用不同的衍生化试剂。最后，该衍生化方法被用于寻找结直肠癌（CRC）患者的潜在生物标志物，识别出52种与多条关键代谢通路（包括氨基酸代谢、TCA循环、脂肪酸代谢、丙酮酸代谢和肠道菌群代谢）相关的CCMs。这种创新的极性调节衍生化-LC-MS方法被证明是探测各种生物样本全球代谢组的高分离效率和灵敏度的有价值工具。
• N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Gibson Keith Hopkinson

  公开号：US20100075942A1

  公开（公告）日：2010-03-25

  The invention concerns benzamide derivatives of Formula (I) wherein R 1a , R 1b , R 1c , R 2 , R 3 , R 4 , W, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of histone deacetylase (HDAC).

  本发明涉及公式（I）的苯甲酰胺衍生物，其中R1a、R1b、R1c、R2、R3、R4、W、m和n具有描述中定义的任何含义；它们的制备过程，含有它们的制药组合物以及它们在制造用作抗增殖剂的药物，用于预防或治疗对组蛋白去乙酰化酶（HDAC）抑制敏感的肿瘤或其他增殖性疾病。
• Verfahren zur Herstellung von Urethanen
  申请人：BAYER AG

  公开号：EP0027940A1

  公开（公告）日：1981-05-06

  Die Erfindung betrifft ein verbessertes Verfahren zur Herstellung von Urethanen durch Umsetzung von Harnstoff oder Polyureten mit primären Aminen und Alkoholen im Temperaturbereich von 120 bis 350° C, bei welchem man die Umsetzung in Gegenwart von Veresterungskatalysatoren für Carbonsäuren als Katalysatoren durchführt, und die Verwendung der Verfahrensprodukte als Ausgangsmaterial zur Herstellung von organischen Isocyanaten.

  本发明涉及一种通过在 120 至 350°C 的温度范围内使脲或聚氨酯与伯胺和醇反应来生产聚氨酯的改进工艺，其中反应是在羧酸酯化催化剂作为催化剂存在的情况下进行的，并涉及将工艺产物用作生产有机异氰酸酯的起始原料。